NeuroTalk Support Groups - Medicinova (MNOV) Reports Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ib

NeuroTalk Support Groups (https://www.neurotalk.org/)

- ALS News & Research (https://www.neurotalk.org/als-news-and-research/)

- - Medicinova (MNOV) Reports Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ib (https://www.neurotalk.org/als-news-and-research/252364-medicinova-mnov-reports-positive-fda-feedback-regarding-phase-3-plan-mn-166-ib.html)

MuonOne

09-27-2018 09:16 AM

Medicinova (MNOV) Reports Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ib

Medicinova (MNOV) Reports Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS
Medicinova (MNOV) Reports Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS

ibudilast to phase III study. Full scale phase III studies tend to be the most expensive and the final testing phase before marketing. IF they pass.

All times are GMT -5. The time now is 09:10 AM.